IsoRay receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Perspective Therapeutics Inc (CATX)
Assess today's live Perspective Therapeutics Inc (CATX) share price, performance and insights using our live NYSE: CATX stock exchange data.
Analyse the historical data and Perspective Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Perspective Therapeutics share price buy/sell indicators using real-time data (or discuss the Perspective Therapeutics (CATX) stock price today with other investors in the Perspective Therapeutics NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE CATX share price (ISIN: US46489V3024) to enhance your trading decisions with our free investment tools and resources.
What Is the Perspective Therapeutics Inc Share Price Today?
The Perspective Therapeutics share price today is 4.9300.
What Is the Stock Symbol for Perspective Therapeutics Inc
The stock symbol (or 'ticker') for Perspective Therapeutics Inc is "CATX."
What Stock Exchange Does Perspective Therapeutics Inc Trade On?
Perspective Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Perspective Therapeutics Inc a Good Stock to Buy?
Determining whether Perspective Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Perspective Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Perspective Therapeutics share price buy/sell indicators using real-time data (or discuss the Perspective Therapeutics (CATX) stock price today with other investors in the Perspective Therapeutics NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE CATX share price (ISIN: US46489V3024) to enhance your trading decisions with our free investment tools and resources.
What Is the Perspective Therapeutics Inc Share Price Today?
The Perspective Therapeutics share price today is 4.9300.
What Is the Stock Symbol for Perspective Therapeutics Inc
The stock symbol (or 'ticker') for Perspective Therapeutics Inc is "CATX."
What Stock Exchange Does Perspective Therapeutics Inc Trade On?
Perspective Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Perspective Therapeutics Inc a Good Stock to Buy?
Determining whether Perspective Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
4.9300
-0.0200(-0.40%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.7950
5.0250
52 wk Range
1.6000
6.1600
CATX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.79505.0250
52 wk Range
1.60006.1600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CATX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
13.1333
Upside
+166.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- IsoRay receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- IsoRay receives Investment Bank Analyst Rating Update
- Investing.com
Pro - IsoRay receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics Inc SWOT Analysis
Radiopharmaceutical Pionee | Perspective Therapeutics leads in targeted cancer therapies with its innovative lead-specific chelator technology and diverse pipeline, positioning itself as a key player in the RPT space. |
Clinical Progress | Explore the company's advancing VMT-α-NET program, with expanded patient enrollment and promising initial safety profiles, signaling confidence in its therapeutic potential. |
Financial Outlook | Analysts maintain a strong buy consensus with an average price target of $16, balancing short-term caution against long-term optimism for CATX's platform and pipeline. |
Strategic Advantages | Delve into CATX's decentralized manufacturing strategy and robust patent estate, potentially offering improved efficiency and a competitive edge in commercialization. |
Compare CATX to Peers and Sector
Metrics to compare | CATX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCATXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −6.5x | −0.5x | |
PEG Ratio | 0.40 | −0.11 | 0.00 | |
Price/Book | 2.6x | 3.2x | 2.6x | |
Price / LTM Sales | 620.6x | 17.1x | 3.1x | |
Upside (Analyst Target) | 162.6% | 66.2% | 53.1% | |
Fair Value Upside | Unlock | 13.6% | 7.1% | Unlock |
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.1333
(+166.40% Upside)
Earnings
Latest Release
16/03/2026
EPS / Forecast
-0.51 / -0.35
Revenue / Forecast
43K / 230.65K
People Also Watch
FAQ
What Is the Perspective Therapeutics (CATX) Share Price Today?
The Perspective Therapeutics stock price today is 4.9300 USD.
What Stock Exchange Does Perspective Therapeutics (CATX) Trade On?
Perspective Therapeutics is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Perspective Therapeutics?
The stock symbol (also called a 'ticker') for Perspective Therapeutics is "CATX."
What Is the Current Perspective Therapeutics Market Cap?
As of today, Perspective Therapeutics market cap is 561.6900M USD.
What Is Perspective Therapeutics's (CATX) Earnings Per Share (TTM)?
The Perspective Therapeutics EPS is currently -1.4000 (Trailing Twelve Months).
When Is the Next Perspective Therapeutics Earnings Date?
Perspective Therapeutics's next earnings report will be released on 19/05/2026.
Is CATX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Perspective Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Perspective Therapeutics Stock Split?
Perspective Therapeutics has split 1 times. (See the CATX stock split history page for full effective split date and price information.)
How Many Employees Does Perspective Therapeutics Have?
Perspective Therapeutics has 165 employees.
What is the current trading status of Perspective Therapeutics (CATX)?
As of 18/03/2026, Perspective Therapeutics (CATX) is trading at a price of 4.9300 USD, with a previous close of 4.9500 USD. The stock has fluctuated within a day range of 4.7950 USD to 5.0250 USD, while its 52-week range spans from 1.6000 USD to 6.1600 USD.
What Is Perspective Therapeutics (CATX) Price Target According to Analysts?
The average 12-month price target for Perspective Therapeutics is 13.1333 USD, with a high estimate of 18 USD and a low estimate of 7 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +166.40% Upside potential.
What Is the CATX Premarket Price?
CATX's last pre-market stock price is 5.0000 USD. The pre-market share volume is 378.0000, and the stock has decreased by 0.0500, or 1.0100%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.